The Foundation for Sarcoidosis Research (FSR) has launched an enhanced version of its patient registry, FSR-SARC, to help maximize the impact of patient participation in research. “Now in its tenth year, the Registry has been one of our most powerful tools to elevate patient voices in the advancement of…

Last week, my husband and I took a road trip to see the Yankees play the Reds in Cincinnati, checking another stadium off our bucket list. We went out for brunch before the game and had a nice chat with our waitress, mostly admiring each other’s tattoos. The food, our…

A new study from researchers in Turkey suggests that a ratio taking into account the amount of angiotensin-converting enzyme (ACE) and of lymphocytes, a type of white blood cell — a ratio elevated in patients with recurrent disease after stopping treatment — is a potential biomarker for people with…

This month, I watched the 78th annual Tony Awards, looking forward to performances from the year’s top shows. I’m always hoping to see my new favorites recognized and get ideas for what to attend next. This year’s awards show was extra special, featuring a reunion and medley from the original…

A Partner Grant from the Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) will support a research project focused on possible connections between air pollution and outcomes of people with sarcoidosis. The grant, totaling $100,000 over two years, was awarded to Mark Mallozzi, MD,…

The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half of 2026. The company had this year announced plans to launch this proof-of-concept trial, called BEACON…

Methotrexate appears to take longer to start acting, but is no less effective than the corticosteroid prednisone as a first-line treatment for pulmonary sarcoidosis, according to the early findings of an ongoing Phase 4 clinical trial. The researchers noted that, while methotrexate treatment is associated with a similar number…

Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that can have serious side effects, according to real-world analyses. “New real-world evidence underscores the growing burden of patients…

The prevalence of sarcoidosis, or the proportion of people with the condition in a population, has roughly doubled over the past 30 years in a region in Norway, a large population-based study shows, and the incidence of sarcoidosis, that is, the number of new cases within a given time,…

April has officially been recognized as Sarcoidosis Awareness Month in the U.S., marking a significant milestone for the community and its advocates, according to the Foundation for Sarcoidosis Research (FSR) — which also celebrates its 25th anniversary this year. The recognition by the U.S. Congress was spearheaded by Danny…